These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30471177)

  • 1. Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?
    Cordiner RLM; Pearson ER
    Diabetes Obes Metab; 2019 Apr; 21(4):761-771. PubMed ID: 30471177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE; van den Donk M; Wiersma T
    Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs for type 2 diabetes.
    Med Lett Drugs Ther; 2019 Nov; 61(1584):169-178. PubMed ID: 31770362
    [No Abstract]   [Full Text] [Related]  

  • 5. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.
    Katsiki N; Kazakos K; Triposkiadis F
    Expert Opin Pharmacother; 2022 Dec; 23(17):1957-1974. PubMed ID: 36322877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.
    Nasykhova YA; Tonyan ZN; Mikhailova AA; Danilova MM; Glotov AS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the management of diabetes: therapies for type 2 diabetes.
    Tsoutsouki J; Wunna W; Chowdhury A; Chowdhury TA
    Postgrad Med J; 2020 Oct; 96(1140):610-618. PubMed ID: 32467106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective.
    Saisho Y
    Expert Opin Pharmacother; 2020 Sep; 21(13):1565-1578. PubMed ID: 32521177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
    Nassif ME; Kosiborod M
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S12-S19. PubMed ID: 31741435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New and old glucose lowering drugs; a state-of-the-art review].
    IJzerman RG; Vrijlandt PJWS
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
    Choby B
    FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas.
    Harrower AD
    Curr Med Res Opin; 1985; 9(10):676-80. PubMed ID: 3935376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.
    Cefalu WT; Buse JB; Del Prato S; Home PD; LeRoith D; Nauck MA; Raz I; Rosenstock J; Riddle MC
    Diabetes Care; 2014 Sep; 37(9):2647-59. PubMed ID: 25147257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical efficacy of glimepiride].
    Kaneko T; Sakamoto N
    Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
    [No Abstract]   [Full Text] [Related]  

  • 18. Sulfonylureas and meglitinides: historical and contemporary issues.
    Lamos EL; Stein SA; Davis SN
    Panminerva Med; 2013 Sep; 55(3):239-51. PubMed ID: 24088798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.
    Bachmann KN; Roumie CL; Wiese AD; Grijalva CG; Buse JB; Bradford R; Zalimeni EO; Knoepp P; Dard S; Morris HL; Donahoo WT; Fanous N; Fonseca V; Katalenich B; Choi S; Louzao D; O'Brien E; Cook MM; Rothman RL; Chakkalakal RJ
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00637. PubMed ID: 32881317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.